Meta-analysis of the effects of Hedan Tablets on blood-lipid levels and inflammatory factors in patients with dyslipidemia
HUANG Chengxin1 SUN Yuanlong2 WANG Xiaolong2 LI Lin1 ZHAO Zhejun1 RUAN Xiaofen2
1.Institute of Cardiovascular Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China;
2.Sub-center of National Center for Clinical Medical Research on Cardiovascular Diseases, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China
Abstract：Objective To systematically evaluate the effects of traditional Chinese patent medicines and simple preparations Hedan Tablets on blood-lipid levels and inflammatory factors in patients with dyslipidemia. Methods Clinical randomized controlled trials of Hedan Tablets in the treatment of dyslipidemia were retrieved from PubMed, CNKI, VIP, Wanfang Data, and China Biomedical Literature Service System from inception to March 2022. The meta-analysis of the results of the included literatures was performed by RevMan 5.3 analysis software and Stata 16.0 software. Results A total of 15 clinical randomized controlled trials were included, including 1 227 patients. The results of meta-analysis showed that the total clinical effective rate of the experimental group was higher than that of the control group (OR=0.28, 95%CI: 0.19 to 0.44, P＜0.000 01). Compared with experimental group, serum levels of total cholesterol (MD=0.65, 95%CI: 0.16 to 1.14, P=0.01), triglyceride (MD=0.84, 95%CI: 0.45 to 1.23, P＜0.000 01), low density lipoprotein cholesterol (MD=0.76, 95%CI: 0.08 to 1.44, P=0.03), C-reactive protein (SMD=2.60, 95%CI: 0.50 to 4.69, P=0.02) were higher in the control group, and serum level of high-density lipoprotein cholesterol (MD=-0.41, 95%CI: -0.70 to -0.12, P＜0.000 01) was lower in the control group. There was no significant difference in the total incidence of adverse reactions between the two groups (OR=1.11, 95%CI: 0.71 to 1.72, P=0.65). Meta-regression analysis showed that publication time, sample size, statin type, and medication duration did not affect the effects of Herdan Tablets on blood-lipid levels and inflammatory factors in patients with dyslipidemia. The results of sensitivity analysis showed that the meta-analysis was stable. The funnel plot was basically symmetrical and had no obvious publication bias. Conclusion Hedan Tablets is better than western medicine alone in improving blood-lipid and inflammatory response indexes in patients with dyslipidemia, and does not increase adverse reactions, the effect is worthy of affirmation.
黄程新1 孙元隆2 王肖龙2 李琳1 赵哲俊1 阮小芬2. 荷丹片对血脂异常患者血脂水平及炎症因子影响的meta分析[J]. 中国医药导报, 2023, 20(16): 87-92.
HUANG Chengxin1 SUN Yuanlong2 WANG Xiaolong2 LI Lin1 ZHAO Zhejun1 RUAN Xiaofen2. Meta-analysis of the effects of Hedan Tablets on blood-lipid levels and inflammatory factors in patients with dyslipidemia. 中国医药导报, 2023, 20(16): 87-92.
[1] Lu Y，Zhang H，Lu J，et al. Prevalence of Dyslipidemia and Availability of Lipid-Lowering Medications Among Primary Health Care Settings in China [J]. JAMA Netw Open，2021，4（9）：e2127573.
[2] Kazi DS，Penko JM，Bibbins-Domingo K. Statins for Primary Prevention of Cardiovascular Disease：Review of Evidence and Recommendations for Clinical Practice [J]. Med Clin North Am，2017，101（4）：689-699.
[3] Zhang M，Deng Q，Wang L，et al. Prevalence of dyslipidemia and achievement of low-density lipoprotein cholesterol targets in Chinese adults：A nationally representative survey of 163，641 adults [J]. Int J Cardiol，2018，260：196-203.
[4] 朱纪斌.阿托伐他汀所致不良反应及临床合理用药分析[J].中国医药科学，2019，9（9）：71-73.
[5] Brunham LR，Lansberg PJ，Zhang L，et al. Differential effect of the rs4149056 variant in SLCO1B1 on myopathy associated with simvastatin and atorvastatin [J]. Pharmacogenomics J，2012，12（3）：233-237.
[6] 李敬伟.荷丹片对血脂异常患者脂代谢与C反应蛋白的影响[J].中西医结合心脑血管病杂志，2012，10（6）：665- 666.
[7] 罗海，张婷，王振国.荷丹片联合阿托伐他汀对血脂异常患者血清同型半胱氨酸和炎症因子水平及血管内皮舒张功能的影响[J].中国医药，2020，15（10）：1518-1522.
[8] 张志勇，周国运，程维.荷丹片对老年高脂血症患者超敏C-反应蛋白的影响[J].中西医结合心脑血管病杂志，2015， 13（17）：1988-1989.
[9] 李本华，宋鹰.荷丹片联合阿托伐他汀治疗高脂血症疗效观察[J].中西医结合心脑血管病杂志，2014，12（7）：806- 807.
[10] 杨福梅.阿托伐他汀钙片联合荷丹片治疗混合型高脂血症的疗效观察[J].云南中医中药杂志，2017，38（12）：31-32.
[11] 林莉凌.荷丹胶囊联合阿托伐他汀治疗高脂血症患者血脂情况的临床疗效观察[J].心血管病防治知识，2020，10（17）：18-20.
[12] 杨莹，吴佳丽.荷丹片合用阿托伐他汀治疗混合型高脂血症25例临床观察[J].中国中医药科技，2009，16（3）：166.
[13] 范英丽，朱叶，尹德辉.荷丹片联合阿托伐他汀治疗中青年血脂异常35例[J].医药导报，2014，33（8）：1029- 1031.
[14] 张会敏.辛伐他汀联合荷丹片治疗高脂血症临床观察30例[J].继续医学教育，2014，28（7）：42-43.
[15] 高菲.荷丹片联合辛伐他汀治疗高脂血症临床疗效[J].天津药学，2016，28（2）：41-42.
[16] 刘娅，苏瑶.小剂量辛伐他汀联合荷丹片治疗老年血脂异常疗效及安全性观察[J].检验医学与临床，2013，10（2）：195-196.
[17] 杨兵生.荷丹片合用辛伐他汀治疗混合型高血脂症的疗效及安全性评价[J].现代中西医结合杂志，2008，17（8）：1158-1159.
[18] 展倩丽，付晓丽，田小燕，等.荷丹片联合瑞舒伐他汀钙对高脂血症患者血管内皮功能的影响[J].疑难病杂志，2013，12（10）：761-763.
[19] 康璇，范晓利，张冲.荷丹片与瑞舒伐他汀治疗高脂血症的疗效及安全性评价[J].中国临床研究，2012，25（12）： 1228-1229.
[20] 陈倩.荷丹胶囊联合瑞舒伐他汀治疗老年高脂血症的临床研究[J].现代药物与临床，2019，34（1）：83-87.
[21] 祝晶晶，王守富.血脂异常的中医药研究概述[J].中医研究，2022，35（1）：83-87.
[22] 王丽杰，刘宇翔，李宇.老年人饮食习惯、生活方式与血脂异常的相关性[J].中国医药导报，2022，19（27）：50-53.
[23] 秘红英，宋红霞，王磊，等.从五脏特性出发探析高脂血症的发病机制[J].世界中医药，2021，16（11）：1675-1678.
[24] 李毛毛，黄鑫源，梁乾坤，等.荷叶水提物对实验性肥胖大鼠脂代谢的影响及机制[J].中国应用生理学杂志，2017，33（5）：476-480.
[25] 王语晴，郭婉琴，刘欣欣，等.丹参注射液对高脂血症模型小鼠脂质代谢的影响[J].湖南中医药大学学报，2022， 42（6）：911-916.
[26] 赵志滨，李李，陈欣燕，等.基于数据挖掘的中药复方治疗血脂异常的组方规律及作用机制研究[J].中国医药导报，2021，18（26）：141-146.
[27] 王玲，吴军林，吴清平，等.山楂降血脂作用和机理研究进展[J].食品科学，2015，36（15）：245-248.
京公网安备 11010502046598号